{"id":746016,"date":"2019-06-19T05:45:00","date_gmt":"2019-06-19T05:45:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/astrazeneca-and-mercks-lynparza-olaparib-approved-in-japan-as-first-line-maintenance-therapy-in-patients-with-brca-mutated-advanced-ovarian-cancer\/"},"modified":"2025-05-12T08:57:59","modified_gmt":"2025-05-12T12:57:59","slug":"astrazeneca-and-mercks-lynparza-olaparib-approved-in-japan-as-first-line-maintenance-therapy-in-patients-with-brca-mutated-advanced-ovarian-cancer","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/astrazeneca-and-mercks-lynparza-olaparib-approved-in-japan-as-first-line-maintenance-therapy-in-patients-with-brca-mutated-advanced-ovarian-cancer\/","title":{"rendered":"AstraZeneca and Merck\u2019s LYNPARZA\u00ae (olaparib) Approved in Japan as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer"},"content":{"rendered":"<p class=\"bwalignc\">       LYNPARZA is the Only PARP Inhibitor Approved in Japan     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United<br \/>\n      States and Canada, today announced that Japan\u2019s Pharmaceuticals and<br \/>\n      Medical Devices Agency (PMDA) has approved LYNPARZA as a maintenance<br \/>\n      treatment after first-line chemotherapy in patients with <i>BRCA<\/i>-mutated<br \/>\n      (<i>BRCA<\/i>m) ovarian cancer.\n    <\/p>\n<p>\n      The approval in Japan was based on<b> <\/b>data from the randomized,<br \/>\n      double-blinded Phase 3 SOLO-1 trial which evaluated LYNPARZA as<br \/>\n      maintenance monotherapy compared with placebo in patients with <i>BRCA<\/i>m<br \/>\n      advanced ovarian cancer following first-line platinum-based chemotherapy.\n    <\/p>\n<p>\n      Dave Fredrickson, executive vice-president, oncology, AstraZeneca, said,<br \/>\n      \u201cThis approval in Japan is a critical advance for women with ovarian<br \/>\n      cancer and a <i>BRCA<\/i> mutation. The goals of front-line therapy are<br \/>\n      long-term remission or a cure, yet currently 70% of patients relapse<br \/>\n      within three years of initial treatment. The progression-free survival<br \/>\n      benefit of Lynparza observed in SOLO-1 represents a major step forward<br \/>\n      in our ambition to improve patient outcomes.\u201d\n    <\/p>\n<p>\n      Dr. Roy Baynes, senior vice president and head of global clinical<br \/>\n      development, chief medical officer, Merck Research Laboratories, said,<br \/>\n      \u201cAdvances in understanding the role of <i>BRCA<\/i> mutations and PARP<br \/>\n      inhibition have fundamentally changed how physicians can treat this<br \/>\n      aggressive type of cancer. With the approval of this new indication,<br \/>\n      patients in Japan with <i>BRCA<\/i>-mutated advanced ovarian cancer who<br \/>\n      respond to chemotherapy will have the opportunity to benefit from<br \/>\n      LYNPARZA in the first-line maintenance setting.\u201d\n    <\/p>\n<p>\n      Results from the SOLO-1 trial showed that LYNPARZA reduced the risk of<br \/>\n      disease progression or death by 70% versus placebo following response to<br \/>\n      platinum-based chemotherapy (HR 0.30 [95% CI 0.23-0.41], p&lt;0.001).\n    <\/p>\n<p>\n      LYNPARZA is the only PARP inhibitor approved in Japan. AstraZeneca and<br \/>\n      Merck are exploring additional trials in ovarian cancer, including the<br \/>\n      ongoing Phase 3 PAOLA-1 trial, which is testing LYNPARZA in combination<br \/>\n      with bevacizumab as a first-line maintenance treatment for women with<br \/>\n      advanced, stage IIIB-IV high-grade serous or endometrioid, fallopian<br \/>\n      tube or peritoneal ovarian cancer, regardless of <i>BRCA<\/i> status.\n    <\/p>\n<p>\n      <b>About SOLO-1<\/b>\n    <\/p>\n<p>\n      SOLO-1 was a Phase 3, randomized, double-blinded, placebo-controlled,<br \/>\n      multi-center trial to evaluate the efficacy and safety of LYNPARZA<br \/>\n      tablets (300 mg twice daily) as maintenance monotherapy compared with<br \/>\n      placebo in patients with <i>BRCA<\/i>m advanced ovarian cancer following<br \/>\n      first-line platinum-based chemotherapy. The trial randomized 391<br \/>\n      patients with a deleterious or suspected deleterious germline or somatic <i>BRCA<\/i>1<br \/>\n      or <i>BRCA<\/i>2 mutation who were in clinical complete or partial<br \/>\n      response following platinum-based chemotherapy. Patients were randomized<br \/>\n      (2:1) to receive LYNPARZA or placebo for up to two years or until<br \/>\n      disease progression. Patients who had a partial response at two years<br \/>\n      were permitted to stay on therapy at the investigator\u2019s discretion. The<br \/>\n      primary endpoint was progression-free survival (PFS) and key secondary<br \/>\n      endpoints included time to second disease progression or death, time to<br \/>\n      first subsequent treatment and overall survival.\n    <\/p>\n<p>\n      The data were presented on Oct. 21, 2018, at the Presidential Symposium<br \/>\n      of the ESMO 2018 Congress in Munich, Germany and published<br \/>\n      simultaneously online in the&nbsp;<i>New England Journal of Medicine<\/i>.\n    <\/p>\n<p class=\"bwalignc\">\n      <b>Summary of PFS<\/b><br \/>\n<sup><br \/>\n<b> i,ii<\/b><br \/>\n<\/sup>\n    <\/p>\n<table cellspacing=\"0\" class=\"bwblockalignc bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <i>Lynparza<\/i> (n=260)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          Placebo (n=131)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          Number of patients with event (%)<sup><br \/>\n<b>iii<\/b><br \/>\n<\/sup>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          102 (39)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          96 (73)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          Median (in months)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          Not reached\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          13.8\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          Hazard ratio (95% CI)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\" colspan=\"3\">\n          0.30 (0.23-0.41)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          P-value\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\" colspan=\"3\">\n          p&lt;0.001\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p class=\"bwalignl\">\n      <sup>i Investigator-assessed<\/sup>\n    <\/p>\n<p class=\"bwalignl\">\n      <sup>ii Median (interquartile range) duration of follow-up 40.7 months<br \/>\n      (34.9\u201342.9) for&nbsp;<i>Lynparza<\/i>&nbsp;and 41.2 months (32.2\u201341.6) for<br \/>\n      placebo<\/sup>\n    <\/p>\n<p class=\"bwalignl\">\n      <sup>iii Analysis was done at 50.6% maturity<\/sup>\n    <\/p>\n<p>\n      The SOLO-1 safety profile was in line with that observed in prior<br \/>\n      clinical trials. The most common adverse events (AEs) \u2265 20% were nausea<br \/>\n      (77%), fatigue (64%), vomiting (40%), anemia (39%) and diarrhea (34%).<br \/>\n      The most common \u2265 Grade 3 AEs were anemia (22%) and neutropenia (8%).<br \/>\n      Seventy-one percent of patients on LYNPARZA remained on the recommended<br \/>\n      starting dose. Additionally, 88% of patients on LYNPARZA continued<br \/>\n      treatment without an AE-related discontinuation. Further, 48% of<br \/>\n      patients on LYNPARZA did not have a dose interruption as a result of an<br \/>\n      AE.\n    <\/p>\n<p>\n      <b>About Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      Worldwide, ovarian cancer is the eighth most-commonly diagnosed cancer<br \/>\n      and seventh most-common cause of cancer deaths in women. In Japan, an<br \/>\n      estimated 10,672 new cases were expected to be diagnosed in 2018, with<br \/>\n      approximately 5,215 deaths. For all types of ovarian cancer, the<br \/>\n      five-year relative survival is approximately 47%. For newly-diagnosed<br \/>\n      advanced ovarian cancer, the primary aim of treatment is to delay<br \/>\n      progression of the disease for as long as possible.\n    <\/p>\n<p>\n      <b>About <i>BRCA<\/i> Mutations<\/b>\n    <\/p>\n<p>\n      Breast cancer susceptibility gene 1\/2 (<i>BRCA<\/i>1 and <i>BRCA<\/i>2)<br \/>\n      are human genes that produce proteins responsible for repairing damaged<br \/>\n      DNA and play an important role in maintaining the genetic stability of<br \/>\n      cells. When either of these genes is mutated, or altered, such that its<br \/>\n      protein product either is not made or does not function correctly, DNA<br \/>\n      damage may not be repaired properly, and cells become unstable. As a<br \/>\n      result, cells are more likely to develop additional genetic alterations<br \/>\n      that can lead to cancer.\n    <\/p>\n<p>\n      <b>About LYNPARZA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (olaparib)<\/b>\n    <\/p>\n<p>\n      LYNPARZA is a first-in-class PARP inhibitor and the first targeted<br \/>\n      treatment to potentially exploit DNA damage response (DDR) pathway<br \/>\n      deficiencies, such as <i>BRCA<\/i> mutations, to preferentially kill<br \/>\n      cancer cells. Inhibition of PARP with LYNPARZA leads to the trapping of<br \/>\n      PARP bound to DNA single-strand breaks, stalling of replication forks,<br \/>\n      their collapse and the generation of DNA double-strand breaks and cancer<br \/>\n      cell death. LYNPARZA is being tested in a range of tumor types with<br \/>\n      defects and dependencies in the DDR.\n    <\/p>\n<p>\n      LYNPARZA, which is being jointly developed and commercialized by<br \/>\n      AstraZeneca and Merck, has a broad and advanced clinical trial<br \/>\n      development program, and AstraZeneca and Merck are working together to<br \/>\n      understand how it may affect multiple PARP-dependent tumors as a<br \/>\n      monotherapy and in combination across multiple cancer types.\n    <\/p>\n<p>\n      <b>IMPORTANT SAFETY INFORMATION<\/b>\n    <\/p>\n<p>\n      <b>CONTRAINDICATIONS<\/b>\n    <\/p>\n<p>\n      There are no contraindications for LYNPARZA.\n    <\/p>\n<p>\n      <b>WARNINGS AND PRECAUTIONS<\/b>\n    <\/p>\n<p>\n      <b>Myelodysplastic Syndrome\/Acute Myeloid Leukemia (MDS\/AML): <\/b>Occurred<br \/>\n      in &lt;1.5% of patients exposed to LYNPARZA monotherapy, and the majority<br \/>\n      of events had a fatal outcome. The duration of therapy in patients who<br \/>\n      developed secondary MDS\/AML varied from &lt;6 months to &gt;2 years. All of<br \/>\n      these patients had previous chemotherapy with platinum agents and\/or<br \/>\n      other DNA-damaging agents, including radiotherapy, and some also had a<br \/>\n      history of more than one primary malignancy or of bone marrow dysplasia.\n    <\/p>\n<p>\n      Do not start LYNPARZA until patients have recovered from hematological<br \/>\n      toxicity caused by previous chemotherapy (\u2264Grade 1). Monitor complete<br \/>\n      blood count for cytopenia at baseline and monthly thereafter for<br \/>\n      clinically significant changes during treatment. For prolonged<br \/>\n      hematological toxicities, interrupt LYNPARZA and monitor blood count<br \/>\n      weekly until recovery.\n    <\/p>\n<p>\n      If the levels have not recovered to Grade 1 or less after 4 weeks, refer<br \/>\n      the patient to a hematologist for further investigations, including bone<br \/>\n      marrow analysis and blood sample for cytogenetics. Discontinue LYNPARZA<br \/>\n      if MDS\/AML is confirmed.\n    <\/p>\n<p>\n      <b>Pneumonitis: <\/b>Occurred in &lt;1% of patients exposed to LYNPARZA, and<br \/>\n      some cases were fatal. If patients present with new or worsening<br \/>\n      respiratory symptoms such as dyspnea, cough, and fever, or a<br \/>\n      radiological abnormality occurs, interrupt LYNPARZA treatment and<br \/>\n      initiate prompt investigation. Discontinue LYNPARZA if pneumonitis is<br \/>\n      confirmed and treat patient appropriately.\n    <\/p>\n<p>\n      <b>Embryo-Fetal Toxicity: <\/b>Based on its mechanism of action and<br \/>\n      findings in animals,\n    <\/p>\n<p>\n      LYNPARZA can cause fetal harm. A pregnancy test is recommended for<br \/>\n      females of\n    <\/p>\n<p>\n      reproductive potential prior to initiating treatment.\n    <\/p>\n<p>\n      <i>Females<\/i>\n    <\/p>\n<p>\n      Advise females of reproductive potential of the potential risk to a<br \/>\n      fetus and to use effective contraception during treatment and for 6<br \/>\n      months following the last dose.\n    <\/p>\n<p>\n      <i>Males<\/i>\n    <\/p>\n<p>\n      Advise male patients with female partners of reproductive potential or<br \/>\n      who are pregnant to use effective contraception during treatment and for<br \/>\n      3 months following the last dose of LYNPARZA and to not donate sperm<br \/>\n      during this time.\n    <\/p>\n<p>\n      <b>ADVERSE REACTIONS\u2014First-Line Maintenance <i>BRCA<\/i>m Advanced<br \/>\n      Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226510% of patients in<br \/>\n      clinical trials of LYNPARZA in the <b>first-line maintenance setting<\/b><br \/>\n      for <b>SOLO-1 <\/b>were: nausea (77%), fatigue (67%), abdominal pain<br \/>\n      (45%), vomiting (40%), anemia (38%), diarrhea (37%), constipation (28%),<br \/>\n      upper respiratory tract infection\/influenza\/ nasopharyngitis\/bronchitis<br \/>\n      (28%), dysgeusia (26%), decreased appetite (20%), dizziness (20%),<br \/>\n      neutropenia (17%), dyspepsia (17%), dyspnea (15%), leukopenia (13%), UTI<br \/>\n      (13%), thrombocytopenia (11%), and stomatitis (11%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA in the <b>first-line maintenance setting for<br \/>\n      SOLO-1<\/b> were: decrease in hemoglobin (87%), increase in mean<br \/>\n      corpuscular volume (87%), decrease in leukocytes (70%), decrease in<br \/>\n      lymphocytes (67%), decrease in absolute neutrophil count (51%), decrease<br \/>\n      in platelets (35%), and increase in serum creatinine (34%).\n    <\/p>\n<p>\n      <b>ADVERSE REACTIONS\u2014Maintenance Recurrent Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in<br \/>\n      clinical trials of LYNPARZA in the <b>maintenance setting <\/b>for <b>SOLO-2<\/b><br \/>\n      were: nausea (76%), fatigue (including asthenia) (66%), anemia (44%),<br \/>\n      vomiting (37%), nasopharyngitis\/upper respiratory tract infection<br \/>\n      (URI)\/influenza (36%), diarrhea (33%), arthralgia\/myalgia (30%),<br \/>\n      dysgeusia (27%), headache (26%), decreased appetite (22%), and<br \/>\n      stomatitis (20%).\n    <\/p>\n<p>\n      <b>Study 19: <\/b>nausea (71%), fatigue (including asthenia) (63%),<br \/>\n      vomiting (35%), diarrhea (28%), anemia (23%), respiratory tract<br \/>\n      infection (22%), constipation (22%), headache (21%), decreased appetite<br \/>\n      (21%), and dyspepsia (20%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA in the <b>maintenance setting (SOLO-2\/Study<br \/>\n      19<\/b>) were: increase in mean corpuscular volume (89%\/82%), decrease in<br \/>\n      hemoglobin (83%\/82%), decrease in leukocytes (69%\/58%), decrease in<br \/>\n      lymphocytes (67%\/52%), decrease in absolute neutrophil count (51%\/47%),<br \/>\n      increase in serum creatinine (44%\/45%), and decrease in platelets<br \/>\n      (42%\/36%).\n    <\/p>\n<p>\n      <b>ADVERSE REACTIONS\u2014Advanced g<i>BRCA<\/i>m ovarian cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in<br \/>\n      clinical trials of\n    <\/p>\n<p>\n      LYNPARZA for <b>advanced g<i>BRCA<\/i>m ovarian cancer after 3 or more<br \/>\n      lines of chemotherapy <\/b>(pooled from 6 studies) were: fatigue\/asthenia<br \/>\n      (66%), nausea (64%), vomiting (43%), anemia (34%), diarrhea (31%),<br \/>\n      nasopharyngitis\/upper respiratory tract infection (URI) (26%), dyspepsia<br \/>\n      (25%), myalgia (22%), decreased appetite (22%), and<br \/>\n      arthralgia\/musculoskeletal pain (21%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA for <b>advanced g<i>BRCA<\/i>m ovarian cancer <\/b>(pooled<br \/>\n      from 6 studies) were: decrease in hemoglobin (90%), mean corpuscular<br \/>\n      volume elevation (57%), decrease in lymphocytes (56%), increase in serum<br \/>\n      creatinine (30%), decrease in platelets (30%), and decrease in absolute<br \/>\n      neutrophil count (25%).\n    <\/p>\n<p>\n      <b>ADVERSE REACTIONS\u2014g<i>BRCA<\/i>m, HER2-negative metastatic breast<br \/>\n      cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in <b>OlympiAD<\/b><br \/>\n      were: nausea (58%), anemia (40%), fatigue (including asthenia) (37%),<br \/>\n      vomiting (30%), neutropenia (27%), respiratory tract infection (27%),<br \/>\n      leukopenia (25%), diarrhea (21%), and headache (20%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in <b>OlympiAD<br \/>\n      <\/b>were: decrease in hemoglobin (82%), decrease in lymphocytes (73%),<br \/>\n      decrease in leukocytes (71%), increase in mean corpuscular volume (71%),<br \/>\n      decrease in absolute neutrophil count (46%), and decrease in platelets<br \/>\n      (33%).\n    <\/p>\n<p>\n      <b>DRUG INTERACTIONS<\/b>\n    <\/p>\n<p>\n      <b>Anticancer Agents: <\/b>Clinical studies of LYNPARZA in combination<br \/>\n      with other\n    <\/p>\n<p>\n      myelosuppressive anticancer agents, including DNA-damaging agents,<br \/>\n      indicate a potentiation and prolongation of myelosuppressive toxicity.\n    <\/p>\n<p>\n      <b>CYP3A Inhibitors: <\/b>Avoid concomitant use of strong or moderate<br \/>\n      CYP3A inhibitors. If a strong or moderate CYP3A inhibitor must be<br \/>\n      co-administered, reduce the dose of LYNPARZA. Advise patients to avoid<br \/>\n      grapefruit, grapefruit juice, Seville oranges, and Seville orange juice<br \/>\n      during LYNPARZA treatment.\n    <\/p>\n<p>\n      <b>CYP3A Inducers: <\/b>Avoid concomitant use of strong or moderate CYP3A<br \/>\n      inducers when using LYNPARZA. If a moderate inducer cannot be avoided,<br \/>\n      there is a potential for decreased efficacy of LYNPARZA.\n    <\/p>\n<p>\n      <b>USE IN SPECIFIC POPULATIONS<\/b>\n    <\/p>\n<p>\n      <b>Lactation: <\/b>No data are available regarding the presence of<br \/>\n      olaparib in human milk, its effects on the breastfed infant or on milk<br \/>\n      production. Because of the potential for serious adverse reactions in<br \/>\n      the breastfed infant, advise a lactating woman not to breastfeed during<br \/>\n      treatment with LYNPARZA and for 1 month after receiving the final dose.\n    <\/p>\n<p>\n      <b>Pediatric Use: <\/b>The safety and efficacy of LYNPARZA have not been<br \/>\n      established in pediatric patients.\n    <\/p>\n<p>\n      <b>Hepatic Impairment: <\/b>No adjustment to the starting dose is<br \/>\n      required in patients with mild or moderate hepatic impairment<br \/>\n      (Child-Pugh classification A and B). There are no data in patients with<br \/>\n      severe hepatic impairment (Child-Pugh classification C).\n    <\/p>\n<p>\n      <b>Renal Impairment: <\/b>No adjustment to the starting dose is necessary<br \/>\n      in patients with mild renal impairment (CLcr=51-80 mL\/min) but patients<br \/>\n      should be monitored closely for toxicity. In patients with moderate<br \/>\n      renal impairment (CLcr=31-50 mL\/min), reduce the dose to 200 mg twice<br \/>\n      daily. There are no data in patients with severe renal impairment or<br \/>\n      end-stage renal disease (CLcr \u226430 mL\/min).\n    <\/p>\n<p>\n      <b>INDICATIONS<\/b>\n    <\/p>\n<p>\n      LYNPARZA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:\n    <\/p>\n<p>\n      <b>First-Line Maintenance <i>BRCA<\/i>m Advanced Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      For the maintenance treatment of adult patients with deleterious or<br \/>\n      suspected deleterious germline or somatic <i>BRCA<\/i>-mutated (g<i>BRCA<\/i>m<i><br \/>\n      <\/i>or s<i>BRCA<\/i>m) advanced epithelial ovarian, fallopian tube or<br \/>\n      primary peritoneal cancer who are in complete or partial response to<br \/>\n      first-line platinum-based chemotherapy. Select patients with g<i>BRCA<\/i>m<br \/>\n      advanced epithelial ovarian, fallopian tube or primary peritoneal cancer<br \/>\n      for therapy based on an FDA-approved companion diagnostic for LYNPARZA.\n    <\/p>\n<p>\n      <b>Maintenance Recurrent Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      For the maintenance treatment of adult patients with recurrent<br \/>\n      epithelial ovarian,\n    <\/p>\n<p>\n      fallopian tube, or primary peritoneal cancer, who are in complete or<br \/>\n      partial response to platinum-based chemotherapy.\n    <\/p>\n<p>\n      <b>Advanced g<i>BRCA<\/i>m ovarian cancer<\/b>\n    <\/p>\n<p>\n      For the treatment of adult patients with deleterious or suspected<br \/>\n      deleterious germline <i>BRCA-<\/i>mutated (g<i>BRCA<\/i>m) advanced<br \/>\n      ovarian cancer who have been treated with 3 or more prior lines of<br \/>\n      chemotherapy. Select patients for therapy based on an FDA-approved<br \/>\n      companion diagnostic for LYNPARZA.\n    <\/p>\n<p>\n      <b>g<i>BRCA<\/i>m, HER2-negative metastatic breast cancer<\/b>\n    <\/p>\n<p>\n      In patients with deleterious or suspected deleterious g<i>BRCA<\/i>m<i>, <\/i>human<br \/>\n      epidermal growth factor receptor 2 (HER2)-negative metastatic breast<br \/>\n      cancer who have been treated with chemotherapy in the neoadjuvant,<br \/>\n      adjuvant or metastatic setting. Patients with hormone receptor<br \/>\n      (HR)-positive breast cancer should have been treated with a prior<br \/>\n      endocrine therapy or be considered inappropriate for endocrine therapy.<br \/>\n      Select patients for therapy based on an FDA-approved companion<br \/>\n      diagnostic for LYNPARZA.\n    <\/p>\n<p>\n      <b>Please <\/b><br \/>\n<a href=\"https:\/\/www.azpicentral.com\/lynparza_tb\/lynparza_tb.pdf\" rel=\"nofollow\"><br \/>\n<b>click<br \/>\n      here for complete Prescribing Information, including Patient Information<br \/>\n      (Medication Guide)<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<p>\n      <b>About the AstraZeneca and Merck Strategic Oncology Collaboration<\/b>\n    <\/p>\n<p>\n      In July 2017, AstraZeneca and Merck, known as MSD outside the United<br \/>\n      States and Canada, announced a global strategic oncology collaboration<br \/>\n      to co-develop and co-commercialize LYNPARZA, the world\u2019s first PARP<br \/>\n      inhibitor, and potential new medicine selumetinib, a MEK inhibitor, for<br \/>\n      multiple cancer types. Working together, the companies will develop<br \/>\n      LYNPARZA and selumetinib in combination with other potential new<br \/>\n      medicines and as monotherapies. Independently, the companies will<br \/>\n      develop LYNPARZA and selumetinib in combination with their respective<br \/>\n      PD-L1 and PD-1 medicines.\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, the potential<br \/>\n      to bring new hope to people with cancer drives our purpose and<br \/>\n      supporting accessibility to our cancer medicines is our commitment. As<br \/>\n      part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the largest development<br \/>\n      programs in the industry across more than 30 tumor types. We also<br \/>\n      continue to strengthen our portfolio through strategic acquisitions and<br \/>\n      are prioritizing the development of several promising oncology<br \/>\n      candidates with the potential to improve the treatment of advanced<br \/>\n      cancers. For more information about our oncology clinical trials, visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/clinicaltrials\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/index.html\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and&nbsp;connect with us on&nbsp;<a href=\"https:\/\/twitter.com\/Merck\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"https:\/\/www.facebook.com\/MerckInvents\/\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"https:\/\/www.instagram.com\/merck\/\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/www.youtube.com\/Merck\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and&nbsp;<a href=\"https:\/\/www.linkedin.com\/company\/merck\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2018 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p>\n<img decoding=\"async\" alt=\"\" src=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Media Contacts:     <\/p>\n<p>       Pamela Eisele<br \/>(267) 305-3558     <\/p>\n<p>       Michael Close<br \/>(267) 305-1211     <\/p>\n<p>       Investor Contacts:     <\/p>\n<p>       Teri Loxam<br \/>(908) 740-1986     <\/p>\n<p>       Michael DeCarbo<br \/>(908) 740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Japan\u2019s Pharmaceuticals and Medical Devices Agency (PMDA) has approved LYNPARZA as a maintenance treatment after first-line chemotherapy in patients with BRCA -mutated ( BRCA m) ovarian cancer. The approval in Japan was based on data from the randomized, double-blinded Phase 3 SOLO-1 trial which evaluated LYNPARZA as maintenance monotherapy compared with placebo in patients with BRCAm advanced ovarian cancer following first-line platinum-based chemotherapy. Dave Fredrickson, executive vice-president, oncology, AstraZeneca, said, \u201cThis approval in Japan is a critical advance for women with ovarian cancer and a BRCA mutation. The goals of front-line therapy are long-term remission or a cure, yet currently 70% of patients relapse within three years of initial treatment. The progression-free survival benefit of Lynparza observed in SOLO-1 represents a major step forward in our<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,55,289,56],"class_list":["post-746016","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AstraZeneca and Merck\u2019s LYNPARZA\u00ae (olaparib) Approved in Japan as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/astrazeneca-and-mercks-lynparza-olaparib-approved-in-japan-as-first-line-maintenance-therapy-in-patients-with-brca-mutated-advanced-ovarian-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca and Merck\u2019s LYNPARZA\u00ae (olaparib) Approved in Japan as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer - Merck.com\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Japan\u2019s Pharmaceuticals and Medical Devices Agency (PMDA) has approved LYNPARZA as a maintenance treatment after first-line chemotherapy in patients with BRCA -mutated ( BRCA m) ovarian cancer. The approval in Japan was based on data from the randomized, double-blinded Phase 3 SOLO-1 trial which evaluated LYNPARZA as maintenance monotherapy compared with placebo in patients with BRCAm advanced ovarian cancer following first-line platinum-based chemotherapy. Dave Fredrickson, executive vice-president, oncology, AstraZeneca, said, \u201cThis approval in Japan is a critical advance for women with ovarian cancer and a BRCA mutation. The goals of front-line therapy are long-term remission or a cure, yet currently 70% of patients relapse within three years of initial treatment. The progression-free survival benefit of Lynparza observed in SOLO-1 represents a major step forward in our\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/astrazeneca-and-mercks-lynparza-olaparib-approved-in-japan-as-first-line-maintenance-therapy-in-patients-with-brca-mutated-advanced-ovarian-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-12T12:57:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"14 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/astrazeneca-and-mercks-lynparza-olaparib-approved-in-japan-as-first-line-maintenance-therapy-in-patients-with-brca-mutated-advanced-ovarian-cancer\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/astrazeneca-and-mercks-lynparza-olaparib-approved-in-japan-as-first-line-maintenance-therapy-in-patients-with-brca-mutated-advanced-ovarian-cancer\\\/\",\"name\":\"AstraZeneca and Merck\u2019s LYNPARZA\u00ae (olaparib) Approved in Japan as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/astrazeneca-and-mercks-lynparza-olaparib-approved-in-japan-as-first-line-maintenance-therapy-in-patients-with-brca-mutated-advanced-ovarian-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/astrazeneca-and-mercks-lynparza-olaparib-approved-in-japan-as-first-line-maintenance-therapy-in-patients-with-brca-mutated-advanced-ovarian-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"datePublished\":\"2019-06-19T05:45:00+00:00\",\"dateModified\":\"2025-05-12T12:57:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/astrazeneca-and-mercks-lynparza-olaparib-approved-in-japan-as-first-line-maintenance-therapy-in-patients-with-brca-mutated-advanced-ovarian-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/astrazeneca-and-mercks-lynparza-olaparib-approved-in-japan-as-first-line-maintenance-therapy-in-patients-with-brca-mutated-advanced-ovarian-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/astrazeneca-and-mercks-lynparza-olaparib-approved-in-japan-as-first-line-maintenance-therapy-in-patients-with-brca-mutated-advanced-ovarian-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"contentUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/astrazeneca-and-mercks-lynparza-olaparib-approved-in-japan-as-first-line-maintenance-therapy-in-patients-with-brca-mutated-advanced-ovarian-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca and Merck\u2019s LYNPARZA\u00ae (olaparib) Approved in Japan as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AstraZeneca and Merck\u2019s LYNPARZA\u00ae (olaparib) Approved in Japan as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/astrazeneca-and-mercks-lynparza-olaparib-approved-in-japan-as-first-line-maintenance-therapy-in-patients-with-brca-mutated-advanced-ovarian-cancer\/","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca and Merck\u2019s LYNPARZA\u00ae (olaparib) Approved in Japan as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer - Merck.com","og_description":"AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Japan\u2019s Pharmaceuticals and Medical Devices Agency (PMDA) has approved LYNPARZA as a maintenance treatment after first-line chemotherapy in patients with BRCA -mutated ( BRCA m) ovarian cancer. The approval in Japan was based on data from the randomized, double-blinded Phase 3 SOLO-1 trial which evaluated LYNPARZA as maintenance monotherapy compared with placebo in patients with BRCAm advanced ovarian cancer following first-line platinum-based chemotherapy. Dave Fredrickson, executive vice-president, oncology, AstraZeneca, said, \u201cThis approval in Japan is a critical advance for women with ovarian cancer and a BRCA mutation. The goals of front-line therapy are long-term remission or a cure, yet currently 70% of patients relapse within three years of initial treatment. The progression-free survival benefit of Lynparza observed in SOLO-1 represents a major step forward in our","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/astrazeneca-and-mercks-lynparza-olaparib-approved-in-japan-as-first-line-maintenance-therapy-in-patients-with-brca-mutated-advanced-ovarian-cancer\/","og_site_name":"Merck.com","article_modified_time":"2025-05-12T12:57:59+00:00","og_image":[{"url":"https:\/\/www.businesswire.com\/images\/spacer.gif","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"14 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/astrazeneca-and-mercks-lynparza-olaparib-approved-in-japan-as-first-line-maintenance-therapy-in-patients-with-brca-mutated-advanced-ovarian-cancer\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/astrazeneca-and-mercks-lynparza-olaparib-approved-in-japan-as-first-line-maintenance-therapy-in-patients-with-brca-mutated-advanced-ovarian-cancer\/","name":"AstraZeneca and Merck\u2019s LYNPARZA\u00ae (olaparib) Approved in Japan as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/astrazeneca-and-mercks-lynparza-olaparib-approved-in-japan-as-first-line-maintenance-therapy-in-patients-with-brca-mutated-advanced-ovarian-cancer\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/astrazeneca-and-mercks-lynparza-olaparib-approved-in-japan-as-first-line-maintenance-therapy-in-patients-with-brca-mutated-advanced-ovarian-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif","datePublished":"2019-06-19T05:45:00+00:00","dateModified":"2025-05-12T12:57:59+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/astrazeneca-and-mercks-lynparza-olaparib-approved-in-japan-as-first-line-maintenance-therapy-in-patients-with-brca-mutated-advanced-ovarian-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/astrazeneca-and-mercks-lynparza-olaparib-approved-in-japan-as-first-line-maintenance-therapy-in-patients-with-brca-mutated-advanced-ovarian-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/astrazeneca-and-mercks-lynparza-olaparib-approved-in-japan-as-first-line-maintenance-therapy-in-patients-with-brca-mutated-advanced-ovarian-cancer\/#primaryimage","url":"https:\/\/www.businesswire.com\/images\/spacer.gif","contentUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/astrazeneca-and-mercks-lynparza-olaparib-approved-in-japan-as-first-line-maintenance-therapy-in-patients-with-brca-mutated-advanced-ovarian-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca and Merck\u2019s LYNPARZA\u00ae (olaparib) Approved in Japan as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"d4258a60-a04c-4bf9-a301-f9dce65ff3ef","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/AstraZeneca-and-Mercks-LYNPARZA-olaparib-Approved-in-Japan-as-First-Line-Maintenance-Therapy-in-Patients-with-BRCA-Mutated-Advanced-O-TSPZM.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/746016","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/746016\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=746016"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=746016"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}